150 related articles for article (PubMed ID: 9865679)
1. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
[TBL] [Abstract][Full Text] [Related]
2. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
[TBL] [Abstract][Full Text] [Related]
3. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D
Vaccine; 2001 Mar; 19(17-19):2565-70. PubMed ID: 11257393
[TBL] [Abstract][Full Text] [Related]
4. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
5. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Opin Biol Ther; 2002 Mar; 2(3):335-42. PubMed ID: 11890872
[TBL] [Abstract][Full Text] [Related]
6. Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.
Sato T
Cancer Immunol Immunother; 1996 Nov; 43(3):174-9. PubMed ID: 9001571
[TBL] [Abstract][Full Text] [Related]
7. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.
Berd D; Murphy G; Maguire HC; Mastrangelo MJ
Cancer Res; 1991 May; 51(10):2731-4. PubMed ID: 2021952
[TBL] [Abstract][Full Text] [Related]
8. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
Sato T; Bullock TN; Eisenlohr LC; Mastrangelo MJ; Berd D
Clin Immunol Immunopathol; 1997 Dec; 85(3):265-72. PubMed ID: 9400626
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
[TBL] [Abstract][Full Text] [Related]
10. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
11. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
12. Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.
Berd D
Vaccine; 2003 Jan; 21(7-8):795-7. PubMed ID: 12531362
[TBL] [Abstract][Full Text] [Related]
13. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine.
Sato T; Maguire HC; Mastrangelo MJ; Berd D
Clin Immunol Immunopathol; 1995 Jan; 74(1):35-43. PubMed ID: 7994925
[TBL] [Abstract][Full Text] [Related]
14. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
15. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
19. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
